3 results
Approved WMOWill not start
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.
Approved WMOCompleted
The overall objective of this trial is to evaluate the efficacy and safety of pamrevlumab as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis.
Approved WMOCompleted
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12 years and older).